Sertraline vs Fluoxetine: Nutrient Depletion Comparison
Compare YOUR medications' depletionsFree, 10 seconds →
At a Glance
Sertraline inhibits serotonin reuptake with additional weak dopamine transporter and sigma-1 receptor binding. CTD documents 138 gene interactions — fewer than fluoxetine's 211, reflecting a narrower off-target profile. Melatonin depletion occurs through serotonin pathway disruption but without fluoxetine's direct pineal enzyme suppression, making sertraline less aggressively sleep-disruptive.
Sertraline has 44% bioavailability with a 26-hour half-life and 98.5% protein binding, providing stable once-daily coverage with moderate discontinuation potential.
- ✓Less aggressive melatonin suppression than fluoxetine — better sleep preservation
- ✓138 CTD gene interactions versus fluoxetine's 211 — narrower off-target molecular footprint
- ✓More FDA indications than fluoxetine: adds social anxiety disorder to the shared list
- ✓26-hour half-life provides the balance between smooth coverage and manageable discontinuation
- ✗98.5% protein binding creates displacement risks that fluoxetine's 94% approaches but doesn't match
- ✗GI side effects (nausea, diarrhea) more prominent than fluoxetine — may worsen folate absorption
- ✗Moderate discontinuation potential — not as smooth as fluoxetine's self-tapering pharmacokinetics
- ✗44% bioavailability means more than half of each dose is lost to first-pass metabolism
Patients who want balanced SSRI coverage with less sleep disruption than fluoxetine and more manageable pharmacokinetics than fluoxetine's ultra-long half-life.
Fluoxetine inhibits serotonin reuptake while directly suppressing pineal AANAT enzyme activity — the rate-limiting step in melatonin synthesis. CTD documents 211 gene interactions, the broadest SSRI molecular footprint, spanning serotonin receptors, sigma receptors, norepinephrine pathways, and multiple CYP enzymes. This wider binding profile intensifies melatonin depletion specifically compared to sertraline's more indirect pathway disruption.
Fluoxetine achieves 90% bioavailability with a 48-hour half-life (active metabolite norfluoxetine extends to 4–16 days), providing continuous coverage that eliminates discontinuation syndrome but creates unbroken melatonin suppression.
- ✓Virtually zero discontinuation syndrome — the easiest SSRI to stop taking
- ✓90% bioavailability ensures consistent drug exposure and predictable depletion patterns
- ✓429 ChEMBL RCTs across 238,071 patients — the most studied antidepressant in history
- ✓Weekly formulation available for patients who struggle with daily pill adherence
- ✗211 CTD gene interactions — the broadest SSRI off-target profile, 1.5x sertraline's count
- ✗Direct pineal AANAT suppression causes more aggressive insomnia than sertraline
- ✗Potent CYP2D6 inhibition blocks metabolism of codeine, tamoxifen, and many co-medications
- ✗94% protein binding, combined with long half-life, means drug accumulation takes weeks to resolve
Patients who prioritize withdrawal-free discontinuation, need weekly formulation for adherence, or have multiple conditions requiring fluoxetine's five FDA indications.
Feature Comparison
| Feature | Sertraline | Fluoxetine |
|---|---|---|
| Drug Class | SSRI (+ weak DRI + sigma) | SSRI (broadest binding profile) |
| Nutrients Depleted | 3 — sodium, folate, melatonin | 3 — sodium, folate, melatonin |
| CTD Gene Interactions | 138 documented | 211 documented |
| Half-Life | 26 hours | 48 hours (norfluoxetine 4–16 days) |
| Bioavailability | 44% | 90% |
| Melatonin Impact | Moderate (indirect) | High (direct pineal suppression) |
| Discontinuation Risk | Moderate | Minimal (self-tapering) |
| CYP2D6 Inhibition | Mild | Strong (blocks codeine, tamoxifen) |
Wondering which medication depletes less?
Check your medications free — 10 seconds →Verdict
Both deplete the same three nutrients, but the pharmacological experience differs substantially. Sertraline offers the more moderate profile: 138 CTD gene interactions (vs 211), less aggressive melatonin suppression preserving sleep, and only mild CYP2D6 inhibition avoiding major drug interactions. Fluoxetine brings two unique advantages: virtually zero discontinuation syndrome (the 48-hour half-life self-tapers over weeks) and the most extensive clinical evidence base of any antidepressant (429 RCTs, 238,071 patients). The trade-off is fluoxetine's direct pineal melatonin suppression causing more insomnia and its strong CYP2D6 inhibition creating drug interaction complexity. For sleep-sensitive patients on multiple medications, sertraline is the gentler choice. For patients who may need to stop their antidepressant or who struggle with daily adherence, fluoxetine's pharmacokinetics are uniquely forgiving.
FAQ
References
- [1]CTD (Comparative Toxicogenomics Database): 138 gene interactions for sertraline; 211 for fluoxetine
- [2]ChEMBL bioactivity database: sertraline RCTs across 6 indications; 429 RCTs for fluoxetine (238,071 patients)
- [3]FAERS (FDA Adverse Event Reporting System): 67,356 sertraline reports; 2,659 fluoxetine reports
- [4]PharmGKB pharmacogenomics database: CYP2D6 strong inhibitor for fluoxetine; mild inhibitor for sertraline
- [5]PubMed PMID 19185342 — Cipriani A et al. Comparative efficacy and acceptability of 12 new-generation antidepressants. Lancet. 2009;373(9665):746-758
Check your medications
Check Free →